Abstract:BackgroundA significant number of patients with COVID-19 experience prolonged symptoms, known as Long COVID. Few systematic studies have investigated this population, particularly in outpatient settings. Hence, relatively little is known about symptom makeup and severity, expected clinical course, impact on daily functioning, and return to baseline health.MethodsWe conducted an online survey of people with suspected and confirmed COVID-19, distributed via COVID-19 support groups (e.g. Body Politic, Long COVID Support Group, Long Haul COVID Fighters) and social media (e.g. Twitter, Facebook). Data were collected from September 6, 2020 to November 25, 2020. We analyzed responses from 3762 participants with confirmed (diagnostic/antibody positive; 1020) or suspected (diagnostic/antibody negative or untested; 2742) COVID-19, from 56 countries, with illness lasting over 28 days and onset prior to June 2020. We estimated the prevalence of 203 symptoms in 10 organ systems and traced 66 symptoms over seven months. We measured the impact on life, work, and return to baseline health.FindingsFor the majority of respondents (>91%), the time to recovery exceeded 35 weeks. During their illness, participants experienced an average of 55.9+/- 25.5 (mean+/-STD) symptoms, across an average of 9.1 organ systems. The most frequent symptoms after month 6 were fatigue, post-exertional malaise, and cognitive dysfunction. Symptoms varied in their prevalence over time, and we identified three symptom clusters, each with a characteristic temporal profile. 85.9% of participants (95% CI, 84.8% to 87.0%) experienced relapses, primarily triggered by exercise, physical or mental activity, and stress. 86.7% (85.6% to 92.5%) of unrecovered respondents were experiencing fatigue at the time of survey, compared to 44.7% (38.5% to 50.5%) of recovered respondents. 1700 respondents (45.2%) required a reduced work schedule compared to pre-illness, and an additional 839 (22.3%) were not working at the time of survey due to illness. Cognitive dysfunction or memory issues were common across all age groups (~88%). Except for loss of smell and taste, the prevalence and trajectory of all symptoms were similar between groups with confirmed and suspected COVID-19.InterpretationPatients with Long COVID report prolonged, multisystem involvement and significant disability. By seven months, many patients have not yet recovered (mainly from systemic and neurological/cognitive symptoms), have not returned to previous levels of work, and continue to experience significant symptom burden.FundingAll authors contributed to this work in a voluntary capacity. The cost of survey hosting (on Qualtrics) and publication fee was covered by AA's research grant (Wellcome Trust/Gatsby Charity via Sainsbury Wellcome center, UCL).

Improvement of immune dysregulation in individuals with long COVID at 24-months following SARS-CoV-2 infection

Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection

Immunological dysfunction persists for 8 months following initial mild-moderate SARS-CoV-2 infection

Long COVID manifests with T cell dysregulation, inflammation and an uncoordinated adaptive immune response to SARS-CoV-2

Distinguishing features of Long COVID identified through immune profiling

Long COVID manifests with T cell dysregulation, inflammation, and an uncoordinated adaptive immune response to SARS-CoV-2

Metabolomic and immune alterations in long COVID patients with chronic fatigue syndrome

Characterizing long COVID in an international cohort: 7 months of symptoms and their impact

SARS-CoV-2-specific CD8+ T cells from people with long COVID establish and maintain effector phenotype and key TCR signatures over 2 years

A Longitudinal Study of COVID-19 Sequelae and Immunity: Baseline Findings

Sex differences and immune correlates of Long COVID development, persistence, and resolution

Symptoms and risk factors for long COVID in non-hospitalized adults

Immune Responses in Discharged COVID-19 Patients With and Without Long COVID Symptoms

Long COVID prevalence and impact on quality of life 2 years after acute COVID-19

Sex differences and immune correlates of Long Covid development, symptom persistence, and resolution

Impact of COVID-19 vaccination on symptoms and immune phenotypes in vaccine-naïve individuals with Long COVID

Long-COVID improves in 50% of patients after a year in a Midwestern cohort

Tissue-based T cell activation and viral RNA persist for up to 2 years after SARS-CoV-2 infection

Persistent Exhausted T-Cell Immunity after Severe COVID-19: 6-Month Evaluation in a Prospective Observational Study

Humoral anti-SARS-CoV-2 response in patients with different long COVID phenotypes

Persistent CD19+ B Cell Lymphopenia in Critically Ill COVID-19 Patients 50 Days after Symptom Onset